RNÉ LEADERS USA CONGRESS

Scientific, Clinical & Commercial Development of RNA Therapeutics & Vaccines

September 6-7 2023 Hynes Convention Centre, Boston, USA

Created by



The network for life science executive leaders

www.lsxleaders.com/rnausa #rnaleaders @RNALeaders

A new paradigm for disease prevention

LSX are known for bringing life science leaders together to assess and meet with the most promising up and coming biotech companies. When the first mRNA vaccines hit the market in 2020, our commercial leaders asked us to look at the resurgence of therapeutics targeting or made of RNA with the view to developing a high-level industry conference. And so, RNA Leaders was born.

> RNA therapeutics market estimated to reach over \$25 billion by 2030.

Research and Markets

The 2022 RNA Leaders Series saw **100+ world-class speakers** and over **600+ senior leaders** from around the world join the most comprehensive and only RNA industry-focused events in **Europe (Basel)** in the spring and the **US (Boston)** in the fall.

The community came together to hear the latest advances in RNA chemistry and get clinical updates from the companies developing new therapies with over **750+ partnering meetings!**

The explosion of the RNA field continues, and RNA medicines are at a critical moment in time. At first in wake of the pandemic **mRNA vaccines dominated the headlines,** although this is still the case mRNA therapeutics and vaccines to treat other infectious diseases and therapeutics like cancer are also taking centre stage.

Huge advances are also being made in **RNAi** and antisense technologies as our understanding of the chemistry evolves and **AI platform progress discovery**.

With that in mind, we can't wait to bring the community together, face-to-face, in fall 2023 for the second annual RNA Leaders USA Congress.

And in the words of Moderna's CSO, Melissa Moore,

"When I saw some other speakers who had been invited I felt this would be a really great place to connect with and network with my peers".

So, if you're passionate about all things RNA please join us, and more than **400 biotech**, pharmaceutical, investment, regulatory and scientific professionals at the **RNA Leaders USA Congress in September 2023.**





RNA Partners

Diamond Partner



Gold Partners



RNA Partners

Silver Partners





Supporting Partners





Ram Aiyar CEO, Korro Bi



Fouad Atouf SVP, Global Biologics, **US Pharmacopeia**



Annette Bak Head of Advanced Drug Delivery, AstraZeneca



Tom Barnes CEO, Orna Therapeutics



John Boyce CEO, Tiger Gene Venture



Kirk Brown VP Delivery Platform, Beam Therapeutics



Angela Genge CMO, QurAlis



Matthias Hackl CEO, TAmiRNA



Tamar Grossman Global Head of RNA, Gene Therapy & Delivery, Janssen



Matthew Hawryluk VP, CBO, Gritstone



June Kim CMC Lead, CEPI



Akihiro Ko, CEO, Elixirgen



Pallavi Lonkar VP, Head of Bioanalytical, DMPK, PenGen



Andreas Kuhn SVP RNA Biochemistry & Manufacturing, BioNTech SE



Jayesh Kulkarni CSO, Nanovation Therapeutics



Alex Kerr Senior Applications Scientist, Unchained Labs



Mikko Turunen CSO, RNatives



www.lsxleaders.com/rnausa



Huw Nash COO & CBO, Stoke Therapeutics



Lykke Pedersen Head of RNA Therapeutics, **Abzu**



Kevin Pong CBO, Anima Biotech



Dmitry Samarsky CTO, Sirnaomicss



Malgorzata Gonciarz AVP of Genetic Medicine, Eli Lilly



Konstantina Skourti-Stathak Principal Scientist, MiNA Therapeutics



Eric Swayze EVP of Research, Ionis



Leslie Williams CEO, Hc Bioscience



Michelle Werner CEO, Alltrna



Peng Yue CEO, ReviR Therapeutics



Daniel Anderson Professor, Chemical Engineering & Institute for Medical Engineering & Science, **MIT**



Olivier Tytgat Business Development Analyst, Ziphius Vaccines



Derek Hicks CBO, Intellia Therapeutic



Pierre Cote Head of Strategic Partnership & Innovation, mRNA, Sanofi



Nick Davis Founder & CTO, HOVANA



Vishal Doshi CEO, AUM Biosciences



Shanthi Ganesh Director, Discovery Research, Dicerna Pharmaceuticals



Vasant Jadhav SVP, Alnylam Pharmaceuticals



Aimee Edinger Professor, Developmental & Cell Biology & Chancellors Fellow, **UC Irvine**



Mike Flanagan CSTO, Avidity Biosciences



Nagy Habib Founder & Head of R&D, MiNA Therapeutics



Nate Spangler Sr Director, Innovation & Strategy, Aldevron



Alicia Irurzun - Lafitte Partner, UCB Ventures



Mahesh Karande CEO, Omega Therapeutics



Clara Assouline Senior Director, Corporate Development & Marketing, Anima Biotech



Karin Kleinhans Partner, MRL Ventures Fund



Cesar Lopez Camacho Principal Investigator, University of Oxford



Josh Mandel-Brehm CEO, CAMP4 Therapeutics



Nick Marsh Senior Director & Head of Molecular Pharmacology, Arrakis



Can Ozbal CEO, Momentum Biotechnologies

8



Guillaume Pfefer CEO, Senda Bioscience




Gerhard Schneider Head of Production, AGC Biologics



Pedro Serrano Senior Director, Head of RNA & Protein Modulation, **Takeda**



Frédéric Legros Chairman & CEO, Arthex Biotech



Raja Mathiazhakan Principal Scientist, Northern RNA



Shraddha Sharma Associate Director, mRNA Center of Excellence, Sanofi



Dietrich Stephan CEO, Neubase Therapeutics



Patrick Thiaville CTO, Nucleic Acids Exothera



Dushyant Varshney CTO, Arcturus Therapeutics



Amy Walker Director of Discovery, 4basebio



Sheri Ambriz Senior Director – Technical Solutions, Asymchem



Dominic Reynolds Head of Drug Discovery, Remix Therapeutics



Tim Luker VP of Venture Science, **Eli Lilly**



Anna Perdrix Rosell Co-CEO & Founder, Sixfold



Carsten Rudolph Co-Founder and CEO, Ethris



CSO, Cartesian Therapeutics



Dee Datta CEO, Switch Therapeutics



Gareth Bolitho Commercial Managerr, Particle Works



Jay Barth CMO, Ascidian Therapeutics



Leo Qian Co-Founder & VP, Discovery Research, Entrada Therapeutics



Romesh Subramanian CEO President, Ascidian Therapeutics



Anastasija Nufer BigOmics



Andrew Ferguson VP, Clinical Development, Gritstone bio



Karin Kleinhans Partner, MRL, Ventures Fund



Uli Stilz Head of Bio Innovation Hub Transformative Research Unit, Novo Nordisk



Jing Zhu VP, Nucleic acid technology, **Arranta Bio**



Sudip Das Professor of Pharmaceutics & Drug Delivery, Butler University



Tej Pavoor COO, **Laronde**



Camden Cutright Business Development Director, Micropore Technologies



Gabriel Helmlinger VP & Head of Translational & Clinical, Biorchestra



David Madge VP, **WuXi AppTec**



Scott Laneman Director, Innovation, Specialty Chemicals & Engineered Materials, Entegris



Eszter Békefi Proposal Manager, ACC Biologics



Amy Espeseth SVP, Infectious Disease and Vaccines Laronde



Mark DeMario VP for Clinical Developmentr, **BioNTech**



Iris Grossman CTO, Eleven Therapeutics



Alex Philippidis Senior Business Editor, Genetic Engineering & Biotechnology News



Christalyn Rhodes Associate VP of Genetic Medicine External Partnerships & Academic Collaborations, **Eli Lilly**



Ariel Weinberger CEO, Autonomous Therapeutics



David Davidson CMO, Tessera Therapeutics



Dillon Flood Co-Founder & Scientific Director, Elsie Biotechnologies



May Guo CCO, Synthgene



James Carrol Managing Director, Life Science Investments, Wharton Alumni Angels



Daniel Quevedo Senior Manager, Business Development & Strategy, METis Therapeutics



Javier Giménez Product Manager, Certest



Yannick Fillon Head of Oligonucleotide Process Chemistry, Biogen



Nate Spangler Sr Director, Innovation and Strategy, Micropore Technologies



Katerina Krumova Director of Delivery Sciences, Laronde



Ryan Cross Senior Science Correspondent, Endpoints News



Jim Weterings Senior Director, Head of Technology Development, Sirnaomics



Sridhar Narayan Head of Chemistry, ReVir Therapeutics



Michael Rosenzweig EVP of Portfolio Strategy and Product Development, Capstan Therapeutics

Event at a Glance

Day 1 6 September 2023						
Face-to-face 1-2-1 Partnering						
Main Content						
RNA LEADERS MORNING KEYNOTE PLENARY						
Track 1	Track 2	Track 3				
Oligo Based Therapeutics Track	mRNA Therapeutics &Vaccines Session Track	Next Gen RNA Session Track				
Drinks Reception + Poster						
Day 2 7 September 2023						
Face-to-face 1-2-1 Partnering						
Main Content						
RNA LEADERS MORNING KEYNOTE PLENARY						
Track 1	Track 2	Track 3				
Oligo Based Therapeutics Track	mRNA Therapeutics &Vaccines Session Track	Next Gen RNA Session Track				
CLOSE OF RNA LEADERS 2023						



See the full agenda here

Packages & Pricing

Tickets	Before May. 19	Before Jun. 16	Before Jul. 07	Before Jul. 28	Before Aug. 18	Final Price
Qualified Investor Ticket	\$1,095	\$1,170	\$1,245	\$1,320	\$1,395	\$1,470
NFP / RDA / Association Ticket	\$1,095	\$1,170	\$1,245	\$1,320	\$1,395	\$1,470
Academic / Research Institute / NFP Ticket *	\$1,095	\$1,170	\$1,245	\$1,320	\$1,395	\$1,470
Biotech (Tx / Delivery / Delivery Tech) Ticket	\$2,195	\$2,495	\$2,895	\$3,195	\$3,495	\$3,695
Large Pharmaceutical Company Ticket	\$2,195	\$2,495	\$2,895	\$3,195	\$3,495	\$3,695
All Services Ticket	\$2,495	\$2,795	\$3,095	\$3,495	\$3,795	\$4,095

* Full time academic with an affiliated university email address

Discounts on tickets for groups | **3+** SAVE an extra 20% / **5+** SAVE an extra 30%


Discount automatically applied at checkout


Book your tickets at www.lsxleaders.com/rnausa

2022 Review

234 attendeed the Congress in Bostom in October 2022. Here is the breakdown:







expertise


• Other

Attendee region

•	MA	
	CA	
	NJ	
	NY	
	IN	
•	WI	

Attendee Seniority

70%



Looking to showcase your recent work to the RNA Comunity?

Our dedicated poster session is the perfect way to celebrate your scientific progress with a global RNA Leaders forum. The Poster Zone will be situated in the main exhibition area and there will be a 1 hour dedicated session allocated during the Congress networking drinks on **September 6th**. All posters will also be displayed for the full 2-days of the Congress.

Please note to present a poster, you must be an academic or biotech with an active pipeline and must also be registered attendee. There is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). Please submit an abstract here (no more than 200 words) for consideration. We will contact you one week after the deadline with the result of your submission, if successful, there is an additional fee of **\$95** for all posters presentations. Posters details: should be sized **A0 (841x1189mm)**.



1:1 Partnering

The LSX World Congress features our state-of-the-art 1:1 partnering system.

The dedicated LSX Events app can be used to build your partnering schedule via desktop and your mobile, allowing you to schedule, move and confirm meetings 'on the fly'.


Your partnering experience. Transformed!

Maximise your out-of-session networking time and secure those vital face-to-face meetings in the in the dedicated 1:1 partnering booth area. The partnering system will go live three weeks before the event with your profile filled in from the information provided on registration and allow you to search the entire attendee list for potential partners and book meetings across the two days.





Floor Plan



Attendees are looking for:





If you offer products or services in any of these fields, our biotech and pharmaceutical attendees want to meet you.

To take part, contact ceri@lsxleaders.com




Chen

WuXi AppTec

Why partner with RNA Leaders?

66





Great event for meeting peers in the field and learning about rapid developments on fast growing RNA industry Mikko Turunen, RNatives cso

Why sponsor?



Contact the Team



For questions about sponsoring: Ceri Doyle Head of RNA, Business Development Manager ceri@lsxleaders.com



For questions about marketing: Aneta Dolezalova Marketing Manager

aneta@lsxleaders.com



For questions about anything else: Jade Osei-Tutu Senior Conference Director jade@lsxleaders.com



Or visit us at: www.lsxleaders.com/rnausa